Roger On
Cardiovascular Disease · Sherman Oaks, CANPI 1255334769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,770 and has fallen 86.5% since, to $238 in 2025.
Across 195 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$820
- E.r. Squibb & Sons, L.L.C.$806
- Johnson & Johnson$410
- AstraZeneca$338
- Novartis$297
- Pfizer$285
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,01499%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 26 | $820 |
| E.r. Squibb & Sons, L.L.C. | 23 | $806 |
| Johnson & Johnson | 18 | $410 |
| AstraZeneca | 11 | $338 |
| Novartis | 16 | $297 |
| Pfizer | 12 | $285 |
| Amgen | 10 | $226 |
| Akcea Therapeutics, Inc. | 7 | $215 |
| Lantheus Medical Imaging, Inc. | 3 | $181 |
| Edwards Lifesciences | 6 | $153 |
| Kowa Pharmaceuticals America, Inc. | 5 | $129 |
| Lundbeck LLC | 5 | $129 |
| Actelion Pharmaceuticals US, Inc. | 4 | $97 |
| Amarin Pharma, Inc. | 4 | $90 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $88 |
| Merck | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Novo Nordisk | 4 | $85 |
| Alnylam Pharmaceuticals Inc. | 4 | $84 |
| Abbott | 2 | $50 |
| Bardy Diagnostics, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Bausch Health US, LLC | 2 | $35 |
| Insulet Corporation | 2 | $34 |
| Portola Pharmaceuticals, LLC | 2 | $33 |
| Mannkind Corporation | 2 | $30 |
| Lilly USA, LLC | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,062 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Sherman Oaks
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.